25
Views
1
CrossRef citations to date
0
Altmetric
Review

Cognitive dysfunction in multiple sclerosis: current approaches to clinical management

&
Pages 731-742 | Published online: 10 Jan 2014

References

  • Compston A. The story of Multiple Sclerosis. In: McAlpine's Multiple Sclerosis 3n1 Edition. Compston A, Eber B, Lassmann H, McDonald I, Mettehws B, Wekerle H (Eds). Hartcourt Brace, London, UK, 3–42 (1998).
  • Weinstock-Guttmann B, Jacobs LD. What is new in the treatment of multiple sclerosis? Drugs 59,401–410 (2000).
  • Rao SM. Neuropsychological aspects of multiple sclerosis. In:Multiple Sclerosis: Clinical and Pathogenetic Basis. Raine CS, McFarland HF, Tourtellotte WW (Eds), Chapman & Hall, London, UK, 357–362 (1997).
  • Rao SM, Leo GJ, Ellington L et al. Cognitive dysfunction in MS II: impact on employment and social functioning. Neurology 41, 692–696 (1991).
  • Beatty WW, Blanco CR, Webanks Sl, Paul RII, Hames IKA. Demographic, clinical andcognitive characteristics of MS patients who continue to work. Neural Rehab. 9, 167–173 (1995).
  • Amato MP, Ponziani G, Pracucci G et al Cognitive impairment in early-onset multiple sclerosis: pattern, predictors and impact on everyday life in a 4-year follow-up. Arch. Neural 52, 168–172 (1995).
  • Langdon DW, Thompson AJ. Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome. Mutt. Stier 5,94–100 (1999).
  • Kujala P, Portin R, Ruutianen J. Memory deficits and early cognitive deterioration in multiple sclerosis. Acta Neural Scand 93, 329–335 (1996).
  • Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis. A reappraisal after 10 years. Atrh. Neural 58,1602–1606 (2001).
  • Beatty WW, Monson N. Metamemory in MS. I Clin. Exp. Neuropsychiatry13, 309–327 (1991).
  • Friend KB, Rabin BM, Groninger L, Deluty RII, Bever C, Grattan L. Languagefunctions in patients with multiple sclerosis. Clin. Neuropsychol 13, 78–94 (1999).
  • Kujala P, Portin R, Ruutiainen J. Language functions in incipient cognitive decline in multiple sclerosis. Neural. Sci. 141, 79–86 (1996).
  • Ivnik RJ. Neuropsychological test performance as a function of the duration of MS-related symptomatology. j Clin. PTchiatry39, 304–307 (1978).
  • Marsh GG. Disability and intellectual function in multiple sclerosis. J. Nerv. Ment. Di s 168, 758–762 (1980).
  • Rao SM, Glatt S, Hammeke TA et al. Chronic progressive multiple sclerosis: relationship between cerebral ventricular size and neuropsychological impairment. Alrh. Neural. 42, 678–682 (1985).
  • Heaton RK, Nelson LM, Thompson DS et al. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. J. Consult. Clin. Bychol 53, 103–110 (1985).
  • Rao SM, Hammeke TA, McQuillen MP et al. Memory disturbance in chronic-progressive multiple sclerosis. Arch. Neural. 41, 625–631 (1984).
  • Thornton AE, Raz N. Memory impairment in multiple sclerosis: a quantitative review. Neuropsychologyll, 357–366 (1997).
  • Feinstein A, Kartsounis LD, Miller DH et al Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric and MRI follow-up study. Neural. Neurosurg. Psychiatry 55, 869–876 (1992).
  • Feinstein A, Ron M, Thompson A. A serial study of psychometric and magnetic resonance imaging changes in multiple sclerosis. Brain 116, 569–602 (1993).
  • Lyon-Caen O, Jouvent R, Hauser S et al Cognitive function in recent-onset demyelinating diseases. Arch. Neural 43, 1138–1141 (1986).
  • Grant CM, McDonald WI, Trimble MR et al. Deficient learning and memory in early and middle phases of multiple sclerosis.' Neural. Neurosurg. Pwchiati y47, 250–255 (1984).
  • McIntosh-Michaelis SA, Roberts MH, Wilkinson SM et al The prevalence of cognitive impairment in a community survey of multiple sclerosis. BE J. Clin. Psycho]: 30, 333–348 (1991).
  • Kurtzke JE Rating neurological impairment in multiple sclerosis: an expanded disability status scale (ED55). Neurology33, 1444–1452 (1983).
  • Amato MP, Ponziani G. Quantification of impairment in MS: discussion of the scales in use. Mult. &ler 5(4), 216–219 (1999).
  • Grossman M, Armstrong C, Onishi K et al Patterns of cognitive impairment in relapsing-remitting and chronic-progressive multiple sclerosis. Neuropsych. Neuropsychol &hay. Neural. 7, 194–210 (1994).
  • Filippi M, Alberoni M, Martinelli V et al Influence of clinical variables on neuropsychological performance in multiple sclerosis. Eur. Neural. 34, 324–328 (1994).
  • Nocentini U, Rossini PM, Carlesimo GA et al Patterns of cognitive impairment in secondary progressive stable phase of multiple sclerosis: correlations with MRI findings. Eur. Neural. 45, 11–18 (2001).
  • Roelcke U, Kappos L, Lechner-Scott J et al Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 48, 1566–1571 (1997).
  • Rao SM, Leo GJ, Haughton VM et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 39, 161–166 (1989).
  • Huber SJ, Bornstein RA, Rammohan KW, Christy JA, Chakeres DW, McGhee RB. Magnetic resonance imaging correlates of neuropsychological impairment analysis in multiple sclerosis. Arch. Neural. 54, 1018–1025 (1997).
  • Rovaris M, Filippi M, Falautano M et al Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neumlogy6, 1601–1608 (1998).
  • Hohol MJ, Guttmann CRG, Orav J et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch. Neurol 54, 1018–1025 (1997).
  • Mariani C, Farina E, Cappa SF et al. Neuropsychological assessment in multiple sclerosis: a follow-up study with magnetic resonance imaging. J. Neural. 238, 395–400 (1991).
  • Comi G, Filippi M, Martinelli V et al Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. J. Neural. Sci. 115 (Suppl. 5), 66–73 (1993).
  • Camp SJ, Stevenson VL, Thompson AJ et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Blain 122, 1341–1348 (1999).
  • Clark CM, James G, Li D, Oger J, Paty D, Klonoff H. Ventricular size, cognitive function and depression in patients with multiple sclerosis. Can. J. Neural. Sci 19, 352–356 (1992).
  • Anzola GP, Bevilacqua L, Cappa SF etal. Neuropsychological assessment in patients with relapsing-remitting multiple sclerosis and mild functional impairment: correlation with magnetic resonance imaging. J. Neumsurg Psychiatry53, 142–145 (1990).
  • Maurelli M, Marchioni E, Cerretano R et al Neuropsychological assessment in MS: clinical, neurophysiological and neuroradiological relationships. Acta Neural. Scam 86, 124–128 (1992).
  • Swirsky-Sacchetti T, Mitchell DR, Seward J et al Neuropsychological and structural brain lesions in multiple sclerosis: a regional analysis. Neurology 42, 1291–1295 (1992).
  • Damian MS, Schilling G, Bachmann G, Simon C, Stoppler S, Dorndorf W. White matter lesions and cognitive deficits: relevance of lesion pattern? Acta Neural. Scam/. 90, 430–436 (1994).
  • Miki Y, Grossman RI, Udupa JK et al Isolated U-fiber involvement in MS: preliminary observations. Neurology50, 1301–1306 (1998).
  • Foong J, Rozewicz L, Davie CA, Thompson AJ, Miller DH, Ron MA. Correlates of executive function in multiple sclerosis: the use of magnetic resonance spectroscopy as an index of focal pathology. I Aiumpsychiatry Clin. Aill1E6Ci. 11, 45–50 (1999).
  • Filippi M, Tortorella C, Rovaris M et al Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis.' Neural. Neurosurg. Bychiatry68, 157–161 (2000).
  • J Folstein MF, Folstein SE, McHugh PR. Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. Psychiatr Res. 12(3), 189–198 (1975).
  • Beatty WW Goodkin DE. Screening for cognitive impairment in multiple sclerosis: an evaluation of the Mini-Mental State Examination. Arch. New& 47,297–301 (1990).
  • Swirsky-Sacchetti T, Field HL et al The sensivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis. J. Clin. Psychol. 48,779–786 (1992).
  • Beatty WW Paul RII, Wilbanks SL, Hames IKA, Blanco CR, Goodkin DE. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI) . Neurology 45 (4), 718–723 (1995).
  • Rao SM and the Cognitive Function Study Group of the National Multiple Sclerosis Society. A manual for the Brief Repeatable Battery of Neuropsychological Tests in multiple sclerosis. Medical College of Wisconsin, Milwaukee, WI, USA (1990).
  • Solari A, Mancuso L, Motta A, Mendozzi L, Serrati C. Comparison of two brief neuropsychological batteries in people with multiple sclerosis. Mutt. Scler. 8,169–176 (2002).
  • Aupperle RL, Beatty WW, Shelton FdeNAP, Gontkovsky ST Three screening batteries to detect cognitive impairment in multiple sclerosis. Mutt. Scler. (In press).
  • Basso MR, Beason-Hazen S, Lynn J, Rammohan K, Bornstein RA. Screening for cognitive dysfunction in multiple sclerosis. Arch. Neuml. 53(10), 980–984 (1996).
  • Peyser JM, Rao SM, LaRocca NG, Kaplan E. Guidelines for neuropsychological research in multiple sclerosis. Arch. Neural 47,94–97 (1990).
  • Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporin in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann. Neural 27, 591–605 (1990).
  • Godkin DE, Fisher JS.Treatment of multiple sclerosis with methtrexate. In: Treatment of Multiple Sclerosis: Advanced in Trial Design, Results and future prospectives. Goodkin DE, Rudick RA (Eds), Springer, London, UK, 251–287 (1996).
  • The IFN-I3 Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I.Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4), 655–661 (1993).
  • Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, Arnason BG. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-lb. Neurology 47 (6), 1463–1468 (1996) .
  • •Study is interest, although flawed, since it is the first trial to assess with an experimental design the possible efficacy of IFNI3-lb on cognitive outcomes.
  • Johnson IKP, Brooks BR, Cohen JA etal. Co-polymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The co-polymer 1 Multiple Sclerosis Study Group. Neurology45 (7), 1268–1276 (1995).
  • Weinstein A, Schwid SI, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Atch. Neural 56(3), 319–324 (1999).
  • ••Pivotal Phase III trial focusing on theeffects of glatirarner on cognitive function.
  • Mariani C, Farina E, Cappa SF et al Neuropsychological assessment in multiple sclerosis: a follow-up study with magnetic resonance irnaging.j Neural 238(7), 395–400 (1991).
  • Jacobs LD, Cookfair DL, Rudick RA et al Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neural 39(3), 285–294 (1996).
  • Fischer JS, Priore RL, Jacobs LD et al Neuropsychological effects of interferon beta-la in relapsing multiple sclerosis. Multiple Sclerosis collaborative Research Group. Ann. Neural 48(6), 885–892 (2000).
  • ••Pivotal Phase III trial demonstrating aclear effect of IFNI3-la therapy on cognitive measures.
  • Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch. Neural 46(6), 676–680 (1989).
  • Geisler MW Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch. Neural 53(2), 185–188 (1996).
  • Smits RC, Emmen 1111, Bertelsmann FVV, Kulig BM, van Loenen AC, Polman CH. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology44(9), 1701–1705 (1994).
  • Rossini PM, Pasqualetti P, Pozzilli C et al Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult. Scler 7(6), 354–358 (2001).
  • Bever CT Jr, Anderson PA, Leslie J et al Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neumlogy 47(6), 1457–1462 (1996).
  • Greene YM, Tariot PN, Wishart H etal. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J. Clin. Rychopharmacol 20(3), 350–356 (2000).
  • Mohr DC, Cox D. Multiple sclerosis: empirical literature for the clinical health psychologist. J. Clin. Psychol. 57(4), 479–499 (2001).
  • Allen DN, Goldstein G, Heyman RA, Rondinelli T Teaching memory strategies to persons with multiple sclerosis. J. Rehabil Res. Dev 35(4), 405–410 (1998).
  • Canellopoulou M, Richardson JTE. The role of executive function in imagery mnemonics: evidence from multiple sclerosis. Neuropsychology36,1181–1188 (1998).
  • Mohr DC, Dick LP, Russo D etal. The psychosocial impact of multiple sclerosis: exploring the patient's perspective. Health Psychol. 18(4), 376–382 (1999).
  • Prosiegel M, Michael C. Neuropsychology and multiple sclerosis: diagnostic and rehabilitative approaches. J. Neural Sci 115\(Suppl. 5), 51–54 (1993).
  • Jonsson A, Korfitzen EM, Heltberg A, Ravnborg MET, Byskov-Ottosen E. Effects of neuropsychological treatment in patients with multiple sclerosis. Acta Neural Scand. 88(6), 394–400 (1993).
  • Plohmann AM, Kappos L, Ammann W et al. Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J. Neural. Neurosurg. Psychiatry 64(4), 455–462 (1998).
  • •Demonstrates the effectiveness of cognitive rehabilitation techniques.
  • Rodgers D, Khoo K, MacEachen M, Oven M, Beatty WW Cognitive therapy for multiple sclerosis: a preliminary study. Altern. Ther. Health Med. 2(5), 70–74 (1996).
  • Benedict RII, Shapiro A, Priore R, Miller C, Munschauer F, Jacobs L. Neuropsychological counseling improves social behavior in cognitively-impaired multiple sclerosis patients. Mult. Scler 6(6), 391–396 (2000).
  • Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigi0 for the treatment of fatigue in multiple sclerosis: a two centre Phase 2 study. Neural. Neurosurg. Psychiaby 72(2), 179–183 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.